Get started
Author

Mari T. Peltola

TMPRSS2 Fusions with Oncogenic ETS Factors in Prostate Cancer Involve Unbalanced Genomic Rearrangements and Are Associated with HDAC1 and Epigenetic Reprogramming
2006 · Kristiina Iljin, Maija Wolf, et al. · Cancer Research · 241
Reducing Unnecessary Biopsy During Prostate Cancer Screening Using a Four-Kallikrein Panel: An Independent Replication
2010 · Andrew Vickers, Angel Cronin, et al. · Journal of Clinical Oncology · 237
PDF
Immuno‐based detection of extracellular vesicles in urine as diagnostic marker for prostate cancer
2015 · Diederick Duijvesz, C. Yin L. Versluis, et al. · International Journal of Cancer · 162
PDF
A Four-Kallikrein Panel Predicts Prostate Cancer in Men with Recent Screening: Data from the European Randomized Study of Screening for Prostate Cancer, Rotterdam
2010 · Andrew J. Vickers, Angel M. Cronin, et al. · Clinical Cancer Research · 120
A four-kallikrein panel for the prediction of repeat prostate biopsy: data from the European Randomized Study of Prostate Cancer Screening in Rotterdam, Netherlands
2010 · A Gupta, M J Roobol, et al. · British Journal of Cancer · 111
PDF
Intact Free Prostate-Specific Antigen and Free and Total Human Glandular Kallikrein 2. Elimination of Assay Interference by Enzymatic Digestion of Antibodies to F(ab‘)2 Fragments
2006 · Ville Väisänen, Mari T. Peltola, et al. · Analytical Chemistry · 68
Levels of Beta-Microseminoprotein in Blood and Risk of Prostate Cancer in Multiple Populations
2012 · Christopher A. Haiman, Daniel O. Stram, et al. · JNCI Journal of the National Cancer Institute · 49
PDF
Homogeneous Dual-Parameter Assay for Prostate-Specific Antigen Based on Fluorescence Resonance Energy Transfer
2008 · Tiina Kokko, Tuomo Liljenbäck, et al. · Analytical Chemistry · 47
Improved cancer specificity in PSA assay using Aleuria aurantia lectin coated Eu-nanoparticles for detection
2016 · Henna Kekki, Mari Peltola, et al. · Clinical Biochemistry · 39
PDF
Genetic signature of prostate cancer mouse models resistant to optimized hK2 targeted α-particle therapy
2020 · Mesude Bicak, Katharina Lückerath, et al. · Proceedings of the National Academy of Sciences · 26
PDF
A Common Prostate Cancer Risk Variant 5′ of Microseminoprotein-β (MSMB) Is a Strong Predictor of Circulating β-Microseminoprotein (MSP) Levels in Multiple Populations
2010 · Kevin M. Waters, Daniel O. Stram, et al. · Cancer Epidemiology Biomarkers & Prevention · 21
Can one blood draw replace transrectal ultrasonography‐estimated prostate volume to predict prostate cancer risk?
2013 · Sigrid V. Carlsson, Mari T. Peltola, et al. · British Journal of Urology · 12
Immunoassay for the discrimination of free prostate-specific antigen (fPSA) forms with internal cleavages at Lys145 or Lys146 from fPSA without internal cleavages at Lys145 or Lys146
2011 · Mari T. Peltola, Pauliina Niemelä, et al. · Journal of Immunological Methods · 12
Intact and Internally Cleaved Free Prostate-Specific Antigen in Patients With Prostate Cancer With Different Pathologic Stages and Grades
2011 · Mari T. Peltola, Pauliina Niemelä, et al. · Urology · 11
Phage display aided improvement of a unique prostate-specific antigen (PSA) antibody unreactive with Lys145–Lys146 internally cleaved forms
2015 · Md. Ferdhos Khan Liton, Mari T. Peltola, et al. · Journal of Immunological Methods · 4
Integrated DNA/RNA microarray profiling of hormone-refractory clinical prostate cancers and metastases indicates deregulation of several pathways, including androgen/AR, Hedgehog, MAPK and neuroactive ligand/receptor signalling
2006 · Michael Wolf, Henrik Edgren, et al. · Cancer Research · 1
Monimuotoisuus, yhdenvertaisuus ja osallisuus Finaviassa
2026 · Peltola, Mari · Theseus (Ammattikorkeakoulujen)
Data from A Common Prostate Cancer Risk Variant 5′ of Microseminoprotein-β (MSMB) Is a Strong Predictor of Circulating β-Microseminoprotein (MSP) Levels in Multiple Populations
2023 · Kevin M. Waters, Daniel O. Stram, et al.
Supplementary Tables 1-3 from A Common Prostate Cancer Risk Variant 5′ of Microseminoprotein-β (MSMB) Is a Strong Predictor of Circulating β-Microseminoprotein (MSP) Levels in Multiple Populations
2023 · Kevin M. Waters, Daniel O. Stram, et al.
Supplementary Table S1 from TMPRSS2 Fusions with Oncogenic ETS Factors in Prostate Cancer Involve Unbalanced Genomic Rearrangements and Are Associated with HDAC1 and Epigenetic Reprogramming
2023 · Kristiina Iljin, Maija Wolf, et al.
PDF
Supplementary Figure S2 from TMPRSS2 Fusions with Oncogenic ETS Factors in Prostate Cancer Involve Unbalanced Genomic Rearrangements and Are Associated with HDAC1 and Epigenetic Reprogramming
2023 · Kristiina Iljin, Maija Wolf, et al.
Supplementary Table S3 from TMPRSS2 Fusions with Oncogenic ETS Factors in Prostate Cancer Involve Unbalanced Genomic Rearrangements and Are Associated with HDAC1 and Epigenetic Reprogramming
2023 · Kristiina Iljin, Maija Wolf, et al.
Supplementary Figure S3 from TMPRSS2 Fusions with Oncogenic ETS Factors in Prostate Cancer Involve Unbalanced Genomic Rearrangements and Are Associated with HDAC1 and Epigenetic Reprogramming
2023 · Kristiina Iljin, Maija Wolf, et al.
Supplementary Table S4-S6 from TMPRSS2 Fusions with Oncogenic ETS Factors in Prostate Cancer Involve Unbalanced Genomic Rearrangements and Are Associated with HDAC1 and Epigenetic Reprogramming
2023 · Kristiina Iljin, Maija Wolf, et al.
Data from TMPRSS2 Fusions with Oncogenic ETS Factors in Prostate Cancer Involve Unbalanced Genomic Rearrangements and Are Associated with HDAC1 and Epigenetic Reprogramming
2023 · Kristiina Iljin, Maija Wolf, et al.
Works count: 34
Citation count: 1,161
H-index: 12
I10-index: 14
Year
Topic
Type